NICE advises on use of erlotinib in NSCLC

New guidance from NICE provides recommendations on the use of erlotinib in the treatment of non-small cell lung cancer (NSCLC).


To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us



  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package